Working to identify risk factors for allergies and asthma, then-postdoctoral researcher Nikole Kimes spotted interesting microbial signatures: Babies who developed so-called atopic diseases appeared to lack specific bacteria in their guts that you'd find in most healthy infants.
Now Kimes' Siolta Therapeutics is deep in the throes of an early-stage clinical trial aimed at seeing if its powder-pill mix of bacteria — what's known as a live biotherapeutic product, or LBP — can reset infants' guts.…
